Patheon has completed the acquisition of Roche’s active pharmaceutical ingredient (API) manufacturing facility in Florence, South Carolina, which Patheon announced in November 2016. Patheon has begun integrating the site into its network.

Under the agreement, Patheon acquired the site for an immaterial sum, plus the cost of associated inventory and spare parts. Patheon has also entered into a multi-year supply arrangement with Roche which Patheon expects to help defray the costs associated with running the site for the next few years. Over time, Patheon expects the Florence facility to have a similar financial profile to its other sites in its drug-substance segment.

The Florence site adds a 300,000 square-foot facility with manufacturing capacity for APIs ranging from development to manufacturing services. The addition of this site expands Patheon’s capacity for manufacturing highly potent compounds and adds capabilities to support solid-state chemistry, micronization (small & large), and future commercial spray drying.

The facility’s production space features reactors ranging from 50 to 1,000 liters for simultaneous multiple-product production. The facility is compliant with all applicable regulations and is validated to meet stringent production, quality, cGMP, safety, and environmental standards. The site also provides flexible operations allowing the company to adapt to new production needs and with capabilities in small- and large-scale manufacturing.

The site will serve as Patheon’s flagship US API operation for commercial-scale and mid-scale API production, and will also enhance Patheon’s emerging pharma presence in the US market. This acquisition is Patheon’s sixth in the last five years.

Source: Patheon